Related Experiment Video
Updated: Jul 11, 2026

Quantification of Proliferating Human Antigen-specific CD4+ T Cells using Carboxyfluorescein Succinimidyl Ester
Published on: June 4, 2019
Cytotoxic T-lymphocyte-associated antigen-4
1Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA. stephen_hodi@dfci.harvard.edu
Abstract:
Previously, the development of immune-based therapies has primarily focused on vaccines and cytokines, yielding benefit in a small percentage of patients. Recent advances in our understanding of the function of costimulatory molecules have revitalized enthusiasm in the development of immune therapies for cancer. This family of proteins possesses properties involved in both lymphocyte activation and immune-inhibitory functions. The costimulatory molecule with the greatest translation into the clinic thus far is CTL-associated antigen-4 (CTLA-4). CTLA-4 engagement leads to T-cell inhibition by two principle mechanisms. The first involves competitive binding with CD28 for B7 on the antigen-presenting cell. The second is direct intracellular inhibitory signals mediated by the CTLA-4 cytoplasmic tail. Numerous clinical trials testing the blockade of CTLA-4 signaling with fully human monoclonal antibodies have treated a variety of cancers, with the most experience in the treatment of metastatic melanoma. Significant antitumor activity as well as potential autoimmune-related toxicities have been observed. Further clinical investigation with CTLA-4 blockade, planned clinical trials testing manipulation of other costimulatory molecules, and continued improvement in understanding of costimulatory pathways present a new era of immune therapies for cancer patients.
Insights
Immune therapies targeting the costimulatory molecule CTL-associated antigen-4 (CTLA-4) show promise for cancer treatment. Blocking CTLA-4 signaling can lead to antitumor activity but may also cause autoimmune toxicities.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Cancer immune therapies historically focused on vaccines and cytokines with limited success.
- Advances in understanding costimulatory molecules have renewed interest in cancer immunotherapy.
- Costimulatory molecules regulate both lymphocyte activation and immune inhibition.
Purpose of the Study:
- To review the role of costimulatory molecules, particularly CTLA-4, in cancer immunotherapy.
- To discuss the mechanisms of CTLA-4 mediated T-cell inhibition.
- To highlight clinical trial outcomes and future directions for CTLA-4 blockade and other costimulatory pathway manipulations.
Main Methods:
- Review of existing literature on costimulatory molecules and their role in cancer immunity.
- Analysis of clinical trial data for CTLA-4 blockade therapies.
- Discussion of the mechanisms of T-cell regulation by CTLA-4.
Main Results:
- CTL-associated antigen-4 (CTLA-4) is a key costimulatory molecule with significant clinical translation.
- CTLA-4 blockade using monoclonal antibodies has demonstrated antitumor activity in various cancers, notably metastatic melanoma.
- Observed outcomes include significant antitumor responses alongside potential autoimmune-related toxicities.
Conclusions:
- CTLA-4 blockade represents a promising new era in cancer immunotherapy.
- Further clinical investigation of CTLA-4 blockade and other costimulatory pathways is warranted.
- Understanding costimulatory pathways is crucial for improving immune therapies for cancer patients.
Related Concept Videos
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Tumor Immunotherapy

